As previously reported, Jefferies analyst Surinder Thind downgraded ASGN to Hold from Buy with a price target of $65, down from $70. He believes the faster than expected slowdown in organic growth to mid single digits reflects "a new near-term normal" as headcount growth in the Apex business has stalled and is unlikely to return to previous levels, Thind tells investors. While the consulting business within assignment has been "one bright spot," he believes it will be difficult to sustain upper mid single digit growth without headcount growth, Thind added.